New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons

Regulations by 2FIRSTS.ai
Nov.29.2023
New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons
New Zealand's landmark smoking ban law, aimed at achieving a "smoke-free generation," has been repealed by the new government.

According to a report by Hipertextual, former New Zealand Prime Minister Jacinda Ardern announced a groundbreaking tobacco control law in 2021, with the aim of achieving a "smoke-free generation" and saving thousands of lives. The law received widespread support from health legislators around the world, with several countries announcing plans to follow suit. However, the new government in New Zealand repealed the law before it could be enacted, and openly admitted that the decision was driven by economic interests.

 

New Zealand's smoking ban bill aims to achieve its goals by gradually increasing the legal smoking age. Currently, in New Zealand and many other countries, the legal age for smoking is 18. The initial plan is to raise the age to 19 by 2026, followed by an annual increase of one year thereafter. Eventually, teenagers will no longer be permitted to smoke. Despite potentially appearing strict, this regulation is expected to save millions of lives and cost millions of dollars in healthcare expenses.

 

However, in the election, the newly elected government in New Zealand has promised to implement a historic tax reduction, which requires a complete overhaul. Given that the tobacco industry brings in a significant amount of revenue for the government, the newly elected right-wing coalition government wasted no time in making this decision.

 

Newly-appointed Minister of Finance, Nicola Willis, has announced the repeal of the smoking ban bill. This decision, driven by economic factors, did not originate from the Health Ministry. The tobacco industry contributes approximately $2 billion in tax revenue to the New Zealand government annually, making it an effective avenue for offsetting tax deductions.

 

A recent study suggests that Ardern's smoking ban bill could save $1.3 billion in healthcare costs over the next 20 years. However, this does not offset the profits from tobacco sales, thus making it an insufficiently compelling reason for the new government.

 

Furthermore, the World Health Organization (WHO) stated in its tobacco report that approximately 8 million people die each year globally due to smoking-related causes. Out of this number, 7 million people die directly from smoking, while the remaining 1 million are second-hand smoke inhalers. These individuals do not willingly smoke, yet they tragically lose their lives due to exposure to cigarette smoke.

 

Achieving a smoke-free generation is just one of the many proposed measures by the World Health Organization to prevent health issues caused by tobacco. Other measures include conducting health promotion campaigns to assist people in quitting smoking, issuing graphic health warnings, increasing taxes on tobacco companies, and regulating nicotine-containing products such as e-cigarettes.

 

At the beginning of this year, the Director-General of the organization, Tedros Adhanom Ghebreyesus, stated that only four countries in the world have implemented a comprehensive set of measures following most of the organization's recommendations. These countries include Brazil, Mauritius, Turkey, and the Netherlands. Among the member states of the European Union, only the Netherlands has achieved this feat. However, data shows that approximately 18.4% of the population aged 15 and above reported being daily smokers in 2019. The highest smoking rate was recorded in Bulgaria at 28.7%, while Sweden had the lowest at 6.4%.

 

Fortunately, several countries, such as Portugal, have started implementing the smoking ban law repealed by New Zealand and have also set goals to achieve a smoke-free generation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
JTI Korea launched the Ploom AURA Teal Electric Pop limited edition in South Korea on September 1, 2026, marking the first dual-color design in the Ploom AURA range. The device combines a dark green body with teal accents and is accompanied by matching Front Panel, Back Cover and Pocket Bag accessories. The standalone device is priced at KRW 29,000, with three additional device-and-accessory bundles available. The release continues JTI Korea's use of limited colorways and interchangeable accessories to expand the Ploom AURA portfolio without introducing a new hardware platform.
Sep.03
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives